Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Drug transporters and anthracycline-induced cardiotoxicity.

Huang KM, Hu S, Sparreboom A.

Pharmacogenomics. 2018 Jul 1;19(11):883-888. doi: 10.2217/pgs-2018-0056. Epub 2018 Jul 11.

PMID:
29991332
2.

Development and validation of an analytical method for regorafenib and its metabolites in mouse plasma.

Fu Q, Chen M, Hu S, McElroy CA, Mathijssen RH, Sparreboom A, Baker SD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 15;1090:43-51. doi: 10.1016/j.jchromb.2018.05.005. Epub 2018 May 5.

PMID:
29783173
3.

OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.

Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S.

J Clin Invest. 2018 Feb 1;128(2):816-825. doi: 10.1172/JCI96160. Epub 2018 Jan 16.

4.

Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood-Brain Barrier in Glioblastoma Patients Using an IVIVE-PBPK Modeling Approach.

Li J, Wu J, Bao X, Honea N, Xie Y, Kim S, Sparreboom A, Sanai N.

Clin Cancer Res. 2017 Dec 15;23(24):7454-7466. doi: 10.1158/1078-0432.CCR-17-0983. Epub 2017 Sep 19.

PMID:
28928160
5.

Kinase Inhibitors: The Reality Behind the Success.

Jeon JY, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.

PMID:
28795397
6.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RHJ, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2017 Aug 22;117(5):e3. doi: 10.1038/bjc.2017.217. Epub 2017 Jul 13.

7.

Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity.

Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A.

Clin Transl Sci. 2017 Sep;10(5):412-420. doi: 10.1111/cts.12480. Epub 2017 Jul 8.

8.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

9.

OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.

Drenberg CD, Gibson AA, Pounds SB, Shi L, Rhinehart DP, Li L, Hu S, Du G, Nies AT, Schwab M, Pabla N, Blum W, Gruber TA, Baker SD, Sparreboom A.

Cancer Res. 2017 Apr 15;77(8):2102-2111. doi: 10.1158/0008-5472.CAN-16-2548. Epub 2017 Feb 16.

10.

PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics.

Fohner AE, Sparreboom A, Altman RB, Klein TE.

Pharmacogenet Genomics. 2017 Apr;27(4):164-167. doi: 10.1097/FPC.0000000000000270. No abstract available.

12.

Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors.

Neul C, Schaeffeler E, Sparreboom A, Laufer S, Schwab M, Nies AT.

Trends Pharmacol Sci. 2016 Nov;37(11):904-932. doi: 10.1016/j.tips.2016.08.003. Epub 2016 Sep 19. Review.

PMID:
27659854
13.

Drug Transporters: Advances and Opportunities.

Govindarajan R, Sparreboom A.

Clin Pharmacol Ther. 2016 Nov;100(5):398-403. doi: 10.1002/cpt.454.

PMID:
27718234
14.

Loss of SLCO1B3 drives taxane resistance in prostate cancer.

de Morrée ES, Böttcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA, Mathijssen RH, Burger H, Wiemer EA, Sparreboom A, de Wit R, van Weerden WM.

Br J Cancer. 2016 Sep 6;115(6):674-81. doi: 10.1038/bjc.2016.251. Epub 2016 Aug 18.

15.

A phosphotyrosine switch regulates organic cation transporters.

Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N.

Nat Commun. 2016 Mar 16;7:10880. doi: 10.1038/ncomms10880.

16.

ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression.

Drenberg CD, Hu S, Li L, Buelow DR, Orwick SJ, Gibson AA, Schuetz JD, Sparreboom A, Baker SD.

Clin Transl Sci. 2016 Feb;9(1):51-9. doi: 10.1111/cts.12366. Epub 2016 Feb 4.

17.

Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.

Zimmerman EI, Gibson AA, Hu S, Vasilyeva A, Orwick SJ, Du G, Mascara GP, Ong SS, Chen T, Vogel P, Inaba H, Maitland ML, Sparreboom A, Baker SD.

Cancer Res. 2016 Jan 1;76(1):117-26. doi: 10.1158/0008-5472.CAN-15-0694. Epub 2015 Dec 17.

18.

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia.

Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2016 Jun;99(6):651-60. doi: 10.1002/cpt.315. Epub 2016 Feb 20.

19.

Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.

Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH.

Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8.

PMID:
26345519
20.

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.

de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Br J Clin Pharmacol. 2015 Sep;80(3):560-8. doi: 10.1111/bcp.12707. Epub 2015 Aug 12.

21.

Lysosomal Sequestration Determines Intracellular Imatinib Levels.

Burger H, den Dekker AT, Segeletz S, Boersma AW, de Bruijn P, Debiec-Rychter M, Taguchi T, Sleijfer S, Sparreboom A, Mathijssen RH, Wiemer EA.

Mol Pharmacol. 2015 Sep;88(3):477-87. doi: 10.1124/mol.114.097451. Epub 2015 Jun 24.

22.

Inter-patient variability in docetaxel pharmacokinetics: A review.

Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH.

Cancer Treat Rev. 2015 Jul;41(7):605-13. doi: 10.1016/j.ctrv.2015.04.012. Epub 2015 May 7. Review.

PMID:
25980322
23.

Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.

Vasilyeva A, Durmus S, Li L, Wagenaar E, Hu S, Gibson AA, Panetta JC, Mani S, Sparreboom A, Baker SD, Schinkel AH.

Cancer Res. 2015 Jul 1;75(13):2729-36. doi: 10.1158/0008-5472.CAN-15-0280. Epub 2015 May 7.

24.

Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.

Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A.

Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5231-6. doi: 10.1073/pnas.1424313112. Epub 2015 Apr 6.

25.

Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity.

Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G.

Pharmacogenomics. 2015;16(4):323-32. doi: 10.2217/pgs.14.182.

26.

CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.

Pabla N, Sparreboom A.

Clin Cancer Res. 2015 Mar 15;21(6):1237-9. doi: 10.1158/1078-0432.CCR-14-2551.

27.

Irinotecan pharmacogenetics: a finished puzzle?

Phelps MA, Sparreboom A.

J Clin Oncol. 2014 Aug 1;32(22):2287-9. doi: 10.1200/JCO.2014.56.3387. Epub 2014 Jun 23. No abstract available.

PMID:
24958823
28.

Hepatic uptake transporters and docetaxel disposition in mice-letter.

Sparreboom A, Mathijssen RH.

Clin Cancer Res. 2014 Aug 1;20(15):4167. doi: 10.1158/1078-0432.CCR-14-0949. Epub 2014 Jun 11. No abstract available.

29.

Cisplatin-induced renal injury is independently mediated by OCT2 and p53.

Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A.

Clin Cancer Res. 2014 Aug 1;20(15):4026-35. doi: 10.1158/1078-0432.CCR-14-0319. Epub 2014 Jun 10.

30.

Influence of drug formulation on OATP1B-mediated transport of paclitaxel.

Nieuweboer AJ, Hu S, Gui C, Hagenbuch B, Ghobadi Moghaddam-Helmantel IM, Gibson AA, de Bruijn P, Mathijssen RH, Sparreboom A.

Cancer Res. 2014 Jun 1;74(11):3137-45. doi: 10.1158/0008-5472.CAN-13-3634. Epub 2014 Apr 22.

31.

Determining the optimal dose in the development of anticancer agents.

Mathijssen RH, Sparreboom A, Verweij J.

Nat Rev Clin Oncol. 2014 May;11(5):272-81. doi: 10.1038/nrclinonc.2014.40. Epub 2014 Mar 25. Review.

PMID:
24663127
32.

A snapshot of challenges and solutions in cancer drug development and therapy.

Phelps MA, Sparreboom A.

Clin Pharmacol Ther. 2014 Apr;95(4):341-6. doi: 10.1038/clpt.2014.15.

PMID:
24646480
33.

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.

Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A.

Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7. Erratum in: Br J Cancer. 2017 Jul 13;:.

34.

Uptake carriers and oncology drug safety.

Sprowl JA, Sparreboom A.

Drug Metab Dispos. 2014 Apr;42(4):611-22. doi: 10.1124/dmd.113.055806. Epub 2013 Dec 30. Review.

35.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

36.

Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.

de Wit D, Gelderblom H, Sparreboom A, den Hartigh J, den Hollander M, König-Quartel JM, Hessing T, Guchelaar HJ, van Erp NP.

Cancer Chemother Pharmacol. 2014 Jan;73(1):87-96. doi: 10.1007/s00280-013-2322-7. Epub 2013 Oct 23.

PMID:
24149944
37.

Appropriate chemotherapy dosing in obese patients with cancer.

Lyman GH, Sparreboom A.

Nat Rev Clin Oncol. 2013 Nov;10(11):664. doi: 10.1038/nrclinonc.2013.108-c2. Epub 2013 Oct 8. No abstract available.

PMID:
24101119
38.

Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.

Walker AL, Lancaster CS, Finkelstein D, Ware RE, Sparreboom A.

Am J Physiol Cell Physiol. 2013 Dec 15;305(12):C1223-9. doi: 10.1152/ajpcell.00232.2013. Epub 2013 Aug 28.

39.

Can erlotinib ameliorate cisplatin-induced toxicities?

Sprowl JA, Mathijssen RH, Sparreboom A.

J Clin Oncol. 2013 Sep 20;31(27):3442-3. doi: 10.1200/JCO.2013.50.8184. Epub 2013 Aug 19. No abstract available.

PMID:
23960178
40.

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.

de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, Friberg LE, Elbouazzaoui S, Wiemer EA, van der Holt B, Verweij J, van Schaik RH, Mathijssen RH.

Clin Cancer Res. 2013 Sep 15;19(18):5210-7. doi: 10.1158/1078-0432.CCR-13-0487. Epub 2013 Aug 5.

41.

Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.

Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A.

Clin Pharmacol Ther. 2013 Nov;94(5):585-92. doi: 10.1038/clpt.2013.145. Epub 2013 Jul 17.

42.

Chemotherapy dosing in overweight and obese patients with cancer.

Lyman GH, Sparreboom A.

Nat Rev Clin Oncol. 2013 Aug;10(8):451-9. doi: 10.1038/nrclinonc.2013.108. Epub 2013 Jul 16. Review.

PMID:
23856744
43.

Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.

Furmanski BD, Hu S, Fujita KI, Li L, Gibson AA, Janke LJ, Williams RT, Schuetz JD, Sparreboom A, Baker SD.

Clin Cancer Res. 2013 Aug 15;19(16):4359-4370. doi: 10.1158/1078-0432.CCR-13-0980. Epub 2013 Jun 21.

44.

Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11199-204. doi: 10.1073/pnas.1305321110. Epub 2013 Jun 17.

45.

Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.

Fukuda Y, Takenaka K, Sparreboom A, Cheepala SB, Wu CP, Ekins S, Ambudkar SV, Schuetz JD.

Mol Pharmacol. 2013 Sep;84(3):361-71. doi: 10.1124/mol.113.086967. Epub 2013 Jun 17.

46.

Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?

Burger H, Mathijssen RH, Sparreboom A, Wiemer EA.

Blood. 2013 Jun 13;121(24):4965-6. doi: 10.1182/blood-2013-03-493841. No abstract available.

47.

Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.

Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A.

Mol Cancer Ther. 2013 Aug;12(8):1537-44. doi: 10.1158/1535-7163.MCT-12-0926. Epub 2013 Jun 11.

48.

CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.

de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.

Clin Cancer Res. 2013 Jun 15;19(12):3316-24. doi: 10.1158/1078-0432.CCR-12-3786. Epub 2013 May 2.

49.

Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.

Drenberg CD, Baker SD, Sparreboom A.

Clin Pharmacol Ther. 2013 Mar;93(3):215-9. doi: 10.1038/clpt.2012.247.

PMID:
23419484
50.

Long-term prospective population PK study in GIST patients--response.

Mathijssen RH, de Bruijn P, Eechoute K, Sparreboom A.

Clin Cancer Res. 2013 Feb 15;19(4):950. doi: 10.1158/1078-0432.CCR-12-3807. Epub 2013 Feb 5. No abstract available.

Supplemental Content

Loading ...
Support Center